Class of warrant or right number of securities called by each warrant or right exercised.

No definition available.

Name:	pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
Namespace Prefix:	pcvx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of royalty payment on annual net sales of vaccine products for human health.

+ References

No definition available.

+ Details

Name:	pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth
Namespace Prefix:	pcvx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of royalty payment on net sales of vaccine compositions for animal health.

+ References

No definition available.

+ Details

Name:	pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth
Namespace Prefix:	pcvx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Date the warrants or rights are exercisable, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingCostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=pcvx_SupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAmendmentATwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=pcvx_CommonStockWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=pcvx_PreferredStockWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	May 29, 2018	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Apr. 30, 2023	Oct. 31, 2022	Jan. 31, 2022	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Common stock, shares owned		95,364,831	79,470,670
Warrant exercised		0			0.001	0.001	0.001
Sutro Biopharma, Inc
Related Party Transaction [Line Items]
Common stock, shares owned				1,600,000				1,600,000
Sutro Biopharma, Inc \| License Agreement
Related Party Transaction [Line Items]
Percentage of royalty payment on annual net sales of vaccine products for human health		4.00%
Percentage of royalty payment on net sales of vaccine compositions for animal health		2.00%
Sutro Biopharma, Inc \| Supply Agreement
Related Party Transaction [Line Items]
Expenses related to Supply Agreement		$ 0.0	$ 0.0	$ 2.4
Sutro Biopharma, Inc \| Series C Redeemable Convertible Stock
Related Party Transaction [Line Items]
Warrant to purchase shares of stock									59,276
Warrant purchase price per share									$ 11.5215
Sutro Biopharma, Inc \| Series C Redeemable Convertible Stock \| License Amendment A2
Related Party Transaction [Line Items]
Warrant to purchase shares of stock	59,276
Warrant purchase price per share	$ 11.5215
Warrant exercisable and vests immediately and expires date	May 29, 2018
Sutro Biopharma, Inc \| Common Stock
Related Party Transaction [Line Items]
Warrant to purchase shares of stock									31,857
Warrant purchase price per share									$ 0.79289
Sutro Biopharma, Inc \| Common Stock Warrant
Related Party Transaction [Line Items]
Warrant exercised									30,278
Sutro Biopharma, Inc \| Preferred Stock Warrant
Related Party Transaction [Line Items]
Warrant exercised									16,591